Konstantinos Mitsimponas

Dr. Konstantinos Mitsimponas


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas
SMS. Mehmet
S. Mehmet
RKR. Kennedy
R. Kennedy
KSK. Shakib
K. Shakib

16 March 2023 in Immunologic Research
Verified
Journal Article
Open access
PDF file
VSVasiliki Syrmou
Vasiliki Syrmou
CLChristos Liaskos
Christos Liaskos
NNNiki Ntavari
Niki Ntavari
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas
TSTheodora Simopoulou
Theodora Simopoulou
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
Several cases of vaccine-associated manifestations have been published including cases of inflammatory myositis. Herein, we comprehensively review the literature on the occasion of case of a woman with inflammatory myositis following COVID-19 vaccination. A 67-year-old woman presented with left arm edema, rash, and weakness after the 2nd dose of the BTN162b2 vaccine. Raised muscle enzymes and inflammatory markers with muscle edema on MRI and myositis findings on the electromyogram established the diagnosis. She was successfully treated with methylprednisolone pulses, intravenous immunoglobulin, methotrexate, and hydroxychloroquine. Cases of inflammatory myositis, dermatomyositis, or interstitial lung disease with myositis-specific autoantibodies or myositis-associated autoantibodies within 12 weeks from SARS-CoV-2 vaccination were included. Cases with malignancy, prior or subsequent COVID-19 infection, preexisting myositis/interstitial lung disease (ILD)/dermatomyositis (DM), or other connective tissue diseases were excluded. From our search, 49 cases were identified (mean age: 56.55 + 17.17 years), 59% were women, while 12 patients received the ChAdOx1 vaccine, 27 the BNT162b2, 8 the mRNA-1273, 1 the DB15806, and 1 the Ad26.COV2.S (overall, 70% received mRNA vaccines). Muscle involvement was the most common manifestation (79.5%), followed by skin involvement (53%) and ILD (34.6%), which were more common in the m-RNA vaccinees. Muscle biopsy, MRI findings, and autoantibody profile varied significantly, while successful immunosuppressive treatment was applied in most cases. Inflammatory myositis after COVID-19 vaccination has been well documented worldwide. Current evidence in support of a pathogenic link is challenging due to significant variation in clinical manifestations, radiological, histopathological, and immunological features.

1 October 2017 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
GVG. Vithlani
G. Vithlani
PJP. Santos Jorge
P. Santos Jorge
EBE. Brizman
E. Brizman
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas

1 October 2016 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas
TMT. Moest
T. Moest
CIC. Iliopoulos
C. Iliopoulos
TRT. Rueger
T. Rueger
CMC. Mueller
C. Mueller
KSK.A. Schlegel
K.A. Schlegel

1 September 2016 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
MWMatthias Christian Wurm
Matthias Christian Wurm
IBInes Brecht
Ines Brecht
MLMichael Lell
Michael Lell
KBKathrin Brunner
Kathrin Brunner
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas
CWCornelius von Wilmowsky
Cornelius von Wilmowsky
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare acquired inflammatory skeletal disorder of unknown origin. CRMO was first described by Gideon in 1972 and mainly affects children and young adults of female gender. The CRMO is part of the clinical picture of non-bacterial Osteomyelitis (NBO) and typically presents a relapsing recurring course with both remission and spontaneous exacerbation. CRMO is typically encountered in the limbs and the metaphysis of long bones in particular. Usually the clinical symptoms include painful swellings of the affected regions. This case report describes the rare case of a CRMO of the mandible in association with pyoderma gangraenosum. A 14-year old female caucasian patient, residing in the south of Germany, presented in the oncological outpatient clinic of our Department of Paediatrics and Adolescent Medicine in June 2014 complaining of increasing neck pain and progressive swelling at her left cheek ongoing for about 6 weeks. These symptoms had been occurring quarterly for 4 years, but had never been as pronounced. Blood biochemistry showed a moderately elevated CRP (35 mg/l) and a significantly increased blood sedimentation rate (BSR 48/120 mm). The panoramic radiograph, however, revealed a bone alteration in the left mandibular region. Further investigations confirmed the diagnosis of CRMO. The present case underlines the fact that rare diseases might occasionally present with even more rare symptoms. These occasions can obviously be considered to present a considerable diagnostic challenge.

1 December 2021 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
RCR. Chouhan
R. Chouhan
RPR. Patel
R. Patel
KSK. Shakib
K. Shakib
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas